Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

被引:51
作者
Bi, YZ
Stoy, P
Adam, L
He, B
Krupinski, J
Normandin, D
Pongrac, R
Seliger, L
Watson, A
Macor, JE
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab & Cardiovasc Drug Discovery, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Oncol & Immunol Drug Discovery, Princeton, NJ 08543 USA
关键词
D O I
10.1016/j.bmcl.2003.12.090
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC50's as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1577 / 1580
页数:4
相关论文
共 16 条
  • [1] PHYSIOLOGY OF PENILE ERECTION
    ANDERSSON, KE
    WAGNER, G
    [J]. PHYSIOLOGICAL REVIEWS, 1995, 75 (01) : 191 - 236
  • [2] CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS
    BEAVO, JA
    [J]. PHYSIOLOGICAL REVIEWS, 1995, 75 (04) : 725 - 748
  • [3] The discovery of novel, potent and selective PDE5 inhibitors
    Bi, YZ
    Stoy, P
    Adam, L
    He, B
    Krupinski, J
    Normandin, D
    Pongrac, R
    Seliger, L
    Watson, A
    Macor, JE
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2461 - 2464
  • [4] Boolell M, 1996, Int J Impot Res, V8, P47
  • [5] Eardley I, 1997, Expert Opin Investig Drugs, V6, P1803, DOI 10.1517/13543784.6.12.1803
  • [6] Drugs for the treatment of impotence
    GarciaReboll, L
    Mulhall, JP
    Goldstein, I
    [J]. DRUGS & AGING, 1997, 11 (02) : 140 - 151
  • [7] Phosphodiesterase 5 inhibitors and nitrergic transmission - from zaprinast to sildenafil
    Gibson, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 411 (1-2) : 1 - 10
  • [8] Martel A. M., 1997, Drugs of the Future, V22, P138
  • [9] Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors
    Rotella, DP
    Sun, Z
    Zhu, YH
    Krupinski, J
    Pongrac, R
    Seliger, L
    Normandin, D
    Macor, JE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (26) : 5037 - 5043
  • [10] N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction
    Rotella, DP
    Sun, Z
    Zhu, YH
    Krupinski, J
    Pongrac, R
    Seliger, L
    Normandin, D
    Macor, JE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (07) : 1257 - 1263